German medical company first Sight has been granted conditional approval by Second Sight's to conduct small clinical trial of its new device, the Orion, which could restore some vision to patients with retinitis pigmentosa. That is a small percentage of the 39 million people worldwide who are blind, according to the World Health Organization. The Orion borrows much of its technology from the US Food and Drug Administration previous model, the Argus II , but also includes electrodes implanted directly into the brain to bypass the eye and the optic nerve. The company said people who are blind due to other illnesses could "hypothetically" use the Orion.
German medical company first Sight has been granted conditional approval by Second Sight's to conduct small clinical trial of its new device, the Orion, which could restore some vision to patients with retinitis pigmentosa. The Orion borrows much of its technology from the US Food and Drug Administration previous model, the Argus II , but also includes electrodes implanted directly into the brain to bypass the eye and the optic nerve. The company said people who are blind due to other illnesses could "hypothetically" use the Orion.